FMC - Ottumwa Chain: Fresenius Medical Care Location: 1110 Quincy Ave. # 44, Ottumwa, Iowa, 52501 Rating: Phone: (641) 682-7137 |
Ottumwa Dialysis Chain: Davita Location: 1005 Pennsylvania Ave #101, Ottumwa, Iowa, 52501 Rating: Phone: (641) 682-1531 |
News Archive
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
A groundbreaking research project by the University of Western Sydney is set to investigate how issues such as work, relationships, family, school life, divorce and lifestyle affect the health and wellbeing of Australian men.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
SemBioSys Genetics Inc. provided an update today on its progress on plant-produced Apo AI(Milano) in light of the Apo AI(Milano) license agreement between Pfizer Inc. and The Medicines Company, of Parsippany, New Jersey.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
› Verified 4 days ago
Dialysis is used as a temporary measure in either acute kidney injury or in those awaiting kidney transplant and as a permanent measure in those for whom a transplant is not indicated or not possible. Dialysis facility in medicare covers outpatient maintenance dialysis treatments, training for self-dialysis, self-dialysis support services and self-dialysis equipment and supplies. In some cases, Medicare may cover ambulance transportation when the patient has End-Stage Renal Disease (ESRD), need dialysis, and need ambulance transportation to or from a dialysis facility.
The star rating shows how well a dialysis center delivers care compared to the national average, based on Medicare data. Each dialysis center receives a rating between 1 and 5 stars, with 3 stars representing the national average. A five-star rating means a center has quality of care that is considered 'much above average' compared to other dialysis facilities. A one or two-star rating means that measured health outcomes for that center were below average. The star rating is part of Medicare's work to make data on the quality of patient care easier to understand and use. Patient survey results aren't included in the star rating.